Proxisense has raised further investment from its main investor, Oxford Science Enterprises (OSE). This provides capital to explore new market applications using Proxisense’s unique technologies. By investing further in the business OSE has enabled product and business developments in process analysis in pharmaceutical and biopharmaceutical applications and to support upcoming clinical trials of a novel medical diagnostic tool.
Proxisense lands development capital for market expansion
